Drug intelligence / Profile preview

JZP441

Development stage: Phase 1
Lead developer: Sumitomo Pharma
Modality: Small Molecules
Administration: Oral

Overview

JZP441 is a potent, highly selective oral orexin-2 receptor agonist designed to activate and restore impaired orexin signaling. Orexin is a neuropeptide involved in regulating sleep and wakefulness. By stimulating the orexin-2 receptor, JZP441 aims to exert wake-promoting effects and potentially address symptoms such as excessive daytime sleepiness (EDS) and cataplexy in people with narcolepsy. The drug has also been considered for idiopathic hypersomnia and other sleep disorders associated with EDS. Originally developed by Sumitomo Pharma as DSP-0187, development rights were acquired by Jazz Pharmaceuticals for further clinical advancement[1][3][4][5][6][8].

Other names: intranasal clonazepam

Targets

HCRTR1 (Orexin/hypocretin receptor type 1)HCRTR2 (Orexin/hypocretin receptor type 2)

Beyond the preview

Go deeper on JZP441.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JZP441.

Explore the full profile